Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Nasopharyngeal Carcinoma 39Carcinoma, Non-Small-Cell Lung 30Esophageal Squamous Cell Carcinoma 22Carcinoma, Hepatocellular 21Triple Negative Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Breast Neoplasms 17Advanced Solid Tumor 17Stomach Neoplasms 14Melanoma 14Small Cell Lung Carcinoma 13Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 10Carcinoma, Transitional Cell 10Carcinoma, Renal Cell 10Recurrence 9Solid Tumor 7Sarcoma 7Neoplasm Metastasis 7Liver Neoplasms 7Head and Neck Neoplasms 7Urinary Bladder Neoplasms 5Rectal Neoplasms 5Esophageal Neoplasms 5Advanced Solid Tumors 5Pancreatic Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Cholangiocarcinoma 4

Interventions

Cetuximab 2Alpelisib 2toripalimab 1sintilimab 1rocakinogene sifuplasmid 1raltitrexed 1cabozantinib 1VGX-3100 1Radiotherapy, Intensity-Modulated 1Metformin 1MEDI0457 1Fluorouracil 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Head and Neck Squamous Cell Cancer × toripalimab × Clear all
NCT04856631 2022-12-19

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Unknown
88 enrolled
Head & Neck

Head and Neck Squamous Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡